New joint guidelines by the American College of Rheumatology and National Psoriasis Foundation recommend psoriatic arthritis patients receive a treat-to-target approach, first-line use of tumor necrosis factor inhibitors biologics, and smoking cessation.
ABP 798, a biosimilar candidate for rituximab, met pharmacokinetic, efficacy, and safety endpoints in a trial among participants with rheumatoid arthritis.
Madelaine A. Feldman, MD, touches on new developments in rheumatology including JAK inhibitor research, genetics and epigenetics, and personalized medicine.
Madelaine A. Feldman, MD, FACR, shares about the current standard treatment rheumatoid arthritis and the hurdles to providing optimal treatment.
What are the most overlooked, difficult-to-treat symptoms within menopause?
How much confidence do you have in your treatment target?
This study appears to confirm the role of B cells in the early pathogenesis of RA and sheds light on an avenue for further investigation.
Which additional bone traits, besides bone mineral density, can be used to determine fracture risk? Authors of a new study sought to find out.
Test your knowledge of the featured topics and findings reported at rheumatology’s annual educational gathering.
Answer these 8 questions to test your knowledge of the latest research findings.
An inexpensive and relatively benign supplement may reduce OA inflammation.
After nearly a year of therapy, 84.5% of patients treated with guselkumab achieved at least 90% severity index improvement, compared to 70% of those treated with secukinumab.
Take this 5-question quiz to find out.
Tolsura was approved for patients with blastomycosis, histoplasmosis, and aspergillosis—infections most commonly associated with immunocompromising diseases such as HIV/AIDS or chronic rheumatic disorders.
The interaction of anticitrullinated protein antibody and rheumatoid factor may foretell the response to treatment in patients with rheumatoid arthritis.
Here: 5 challenging questions to test your knowledge.
The smaller, incomplete study is looking into both the efficacy and safety of the longtime therapy for patients with RA.
Repository corticotropin injection’s nearly six-decade history as a therapy has been tumultuous, but has most recently resulted in its use as an auto-immune drug.
Will you recognize Behçet disease when you see it?
The ACTPen was approved on the basis of a pair of clinical trials presented at the 2018 American Society for Clinical Pharmacology & Therapeutics Annual Meeting.
Contrary to current guideline recommendations, a new review argues against routine coeliac disease screening for osteoporosis patients.
Speaking ambitiously, determining the right tests and initial therapies for patients with rheumatoid arthritis could become optimized.
A new meta-analysis found no improvement in symptoms or in quality of life among more than 2000 participants treated for subclinical disease.
The approval was based on a comprehensive data package demonstrating that Hyrimoz matches the reference biologic in terms of safety, efficacy, and quality.
Findings from the most extensive study to analyze the association between HLA-B27 status and manifestations of AS.
Try this short quiz on the first update to the Endocrine Society practice guideline on hirsutism since 2008.
The US Department of Health and Human Services updated guidelines feature key recommendations for young children aged 3-5, youths aged 6-17, adults, older adults, pregnant and post-partum women, as well as adults with chronic health conditions and disabilities.
Take this 5-question quiz for a quick refresher on the ACR guidelines.
What next when methotrexate monotherapy fails? The answer-and 4 more questions on RA treatment-can be found here.
A look at the relationship between disease activity, progression, and low bone mineral density in axial spondyloarthritis.
